Clinical trial · no report yet · Phase 2/Phase 3
NCT03952585
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
- NCT03952585 ↗
- Active not recruiting
- National Cancer Institute (NCI)
- 16 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 10 | |
| Podcasts | 4 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
- Phase
- Phase 2/Phase 3
- Status
- Active not recruiting
- Conditions
- Basaloid Squamous Cell Carcinoma; Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Oropharyngeal Squamous Cell Carcinoma; Papillary Squamous Cell Carcinoma; Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Squamous Cell Carcinoma
- Interventions
- Biopsy Procedure; Biospecimen Collection; Cisplatin; Computed Tomography; Fludeoxyglucose F-18; Image Guided Radiation Therapy; Intensity-Modulated Radiation Therapy; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Arm I (Standard RT + cisplatin) · Active comparator
- Arm II (Reduced RT + cisplatin) · Experimental
- Arm III (Reduced RT + nivolumab) · Experimental
- Enrollment
- 384
- Primary outcomes
- Progression-free Survival (PFS) (Phase II) (Percentage of Participants Alive Without Progression)
- Progression-free Survival (Phase III) (Percentage of Participants Alive Without Progression)
- MD Anderson Dysphagia Inventory (MDADI) Global Quality of Life (QOL) Score
- Sponsor
- National Cancer Institute (NCI) with NRG Oncology
- Start
- Oct 9, 2019
- Primary completion
- Mar 1, 2024
- Results posted
- Yes
- Registry record
- NCT03952585 · updated Jul 2, 2026